

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

BD

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/34593</b> <b>(43) International Publication Date:</b> 13 August 1998 (13.08.98)
<b>(21) International Application Number:</b> PCT/US98/02701 <b>(22) International Filing Date:</b> 6 February 1998 (06.02.98)  <b>(30) Priority Data:</b> 08/797,472 6 February 1997 (06.02.97) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 08/797,472 (CIP) Filed on 6 February 1997 (06.02.97)  <b>(71) Applicant (for all designated States except US):</b> INSPIRE PHARMACEUTICALS, INC. [US/US]; 4222 Emperor Boulevard #470, Durham, NC 27703 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YERXA, Benjamin, R. [US/US]; 1330 Hathaway Road, Raleigh, NC 27608 (US). JACOBUS, Karla, M. [US/US]; 200 Riverwalk Circle, Cary, NC 27511 (US). PENDERGAST, William [GB/US]; 5815 Williamsburg Way, Durham, NC 27713 (US). RIDEOUT, Janet, L. [US/US]; 3101 Morningside Drive, Raleigh, NC 27607 (US).		<b>(74) Agent:</b> HALLUIN, Albert, P.; Howrey & Simon, 1299 Pennsylvania Avenue, N.W., Box 34, Washington, DC 20004-2402 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD OF TREATING DRY EYE DISEASE WITH PURINERGIC RECEPTOR AGONISTS  <b>(57) Abstract</b>  A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5'-triphosphate [UTP], dinucleotides, cytidine 5'-triphosphate [CTP], adenosine 5'-triphosphate [ATP], or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Kazakstan	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

## METHOD OF TREATING DRY EYE DISEASE WITH PURINERGIC RECEPTOR AGONISTS

5

### INTRODUCTION

This application is a continuation-in-part of U.S. Serial No. 08/797,472  
10 filed February 6, 1997.

#### Technical Field

This invention relates to a method of regulating secretions in and around  
15 the eye of a patient by administering purinergic receptor agonists such as certain uridine,  
adenine, or cytidine triphosphates as well as other nucleoside phosphate compounds.

This invention also relates to a method of enhancing drainage of the  
lacrimal system by administering a pharmacologic agent that enhances mucociliary  
clearance of the nasolacrimal duct of a mammal. These agents include certain uridine,  
20 adenine and cytidine triphosphates as well as other nucleoside phosphate compounds.

#### Background of the Invention

There are many situations where it is therapeutically desirable to increase  
the amount of tear fluid produced by the eye. Dry eye disease is the general term for  
25 indications produced by abnormalities of the precorneal tear film characterized by a  
decrease in tear production or an increase in tear film evaporation, together with the  
ocular surface disease that results. Approximately 38 million Americans are affected with  
some type of dry eye disorder. Among the indications that are referred to by the general  
term "dry eye disease" are: keratoconjunctivitis sicca (KCS), age-related dry eye,  
30 Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid,  
blepharitis, corneal injury, infection, Riley-Day syndrome, congenital alacrima,  
nutritional disorders or deficiencies (including vitamins), pharmacologic side effects, eye  
stress and glandular and tissue destruction, environmental exposure to smog, smoke,  
excessively dry air, airborne particulates, autoimmune and other immunodeficient

disorders, and comatose patients rendered unable to blink. The present invention may also be useful as a wash or irrigation solution in conscious individuals, during surgery or to maintain comatose patients or those who cannot blink due to neuromuscular blockade or loss of the eyelids.

5                   A healthy precorneal tear film has several important functions: 1) to protect the cornea from desiccation; 2) to aid in the immune response to infections; 3) to enhance oxygen permeation into the cornea; 4) to allow gliding movement of the eyeball and eyelids; and 5) to help maintain the ocular pressure through osmosis. There are two structures responsible for maintaining the properties of the tear film--the lacrimal glands  
10                   and the conjunctiva (the mucous membrane which surrounds part of the eyeball and inner eyelids). These structures maintain the tear film via regulation of water and electrolyte transport and via mucin release by goblet cells.

                  The progression of dry eye disease is characterized by four main "milestones." The first milestone is a decrease in tear production. In rabbit models, this  
15                   decrease in tear production has been shown to correlate with an increase in tear osmolarity. The second milestone is a loss of mucous-containing conjunctival goblet cells. This decrease in goblet cell density becomes evident several weeks after the onset of decreased tear production. The third milestone in the progression of dry eye disease occurs about 1 year later when desquamation of the corneal epithelium is observed. The  
20                   fourth and last milestone of the disease is a destabilization of the cornea-tear interface (J. Gilbard, *CLAO Journal* 22(2), 141-45 (1996)).

                  Currently, the pharmaceutical treatment of dry eye disease is mostly limited to administration of artificial tears (saline solution) to temporarily rehydrate the eyes. However, relief is short-lived and frequent dosing is necessary. In addition,  
25                   artificial tears often have contraindications and incompatibility with soft contact lenses (M. Lemp, *Cornea* 9(1), S48-550 (1990)). The use of phosphodiesterase inhibitors, such as 3-isobutyl-1-methylxanthine (IBMX) to stimulate tear secretion is disclosed in U.S. Pat. No. 4,753,945 (applicant intends this and all other patent references to be incorporated herein). The effectiveness of these phosphodiesterase inhibitors is currently

being investigated (J. Gilbard, et al., *Arch. Ophthalmol.*, 112, 1614-16 (1994) and 109, 672-76 (1991); idem, *Inv. Ophthalmol. Vis. Sci.* 31, 1381-88 (1990)). Stimulation of tear secretion by topical application of melanocyte stimulating hormones is described in U.S. Pat. No. 4,868,154.

5                   There are many situations where it is therapeutically desirable to increase drainage of the lacrimal system. The lacrimal system has two functioning components: the secretory part, which produces tears, and the excretory part, which drains the tears into the nose. When the lacrimal drainage system is not functioning properly the result can be excessive tearing (epiphora), mucopurulent discharge, and recurrent dacryocystitis (C. Shermataro, et. al., *JAOA*, 94, 229 (1994)). In fact, tearing is one of the most common  
10                   complaints that brings a patient to the ophthalmologist's office (S. T. Conway, *Ophthalmol. Plas. Reconstr. Surg.*, 10, 185 (1994)).

                  The most common malfunction of the lacrimal drainage system is nasolacrimal duct obstruction, which results in stasis of tears in the lacrimal sac. The  
15                   accumulation of fluid and mucus results in tearing and expulsion of mucopurulent material, causing the eyelids to be "stuck together" on awakening in the morning. The lack of clearance of the tear fluid also leads to inflammation and chronic infection of the lacrimal sac and ducts (K. J. Hyde, et. al., *Ophthalmol.*, 95, 1447 (1988); J. A. Blicher, et. al., *Ophthalmol. Plas. Reconstr. Surg.*, 9, 43 (1993); J. A. Mauriello Jr., et. al., *Ophthalmol. Plast. Reconstr. Surg.*, 8, 13 (1992)).  
20                   

                  Nasolacrimal duct obstruction can be divided into two etiologic classes: primary acquired nasolacrimal duct obstruction (PANDO), which is characterized by hyperplasia and fibrosis of the mucosal epithelium, and secondary acquired nasolacrimal duct obstruction (SANDO), which is caused by cancer, inflammation, infection, trauma  
25                   and mechanical problems (G. B. Bartley, *Ophthalmol. Plast. Reconstr. Surg.*, 8, 237 (1992)). An occluded nasolacrimal duct is more common in middle-aged women and infants. In fact, up to 20% of all infants are affected by nasolacrimal duct obstruction with most of them becoming symptom free by their first birthday (J. D. H. Young, et. al., *Eye*, 10, 485 (1996)).

Current treatments for nasolacrimal duct obstruction are mostly invasive or surgical procedures that vary in aggressiveness. Intervention can take the form of probing the duct with a fine catheter; however, this is a difficult and delicate procedure that requires special training and equipment (J. Kassoff, et. al., *Arch. Ophthalmol.*, 113, 1168 (1995); J. D. Griffiths, US Pat 4921485 (1990) and 5062831 (1991); B. B. Becker, et. al., US Pat 5021043 (1991) and 5169386 (1992)). In some cases silastic intubation of the nasolacrimal duct increases drainage of tears through the nasolacrimal duct (R. K. Dortzbach, et. al., *Amer. J. Ophthalmol.*, 94, 585 (1982); H. Al-Hussain, et. al., *Ophthalm. Plas. Reconstr. Surg.*, 9, 32 (1993); J. S. Crawford, et. al. US Pat 4380239 (1983); W. L. Ector, Jr., US Pat 4658816 (1987)). A more aggressive procedure is a dacryocystorhinostomy which surgically creates a new drainage path above the sight of obstruction allowing continuity between the lacrimal sac and the nasal cavity (J. V. Linberg, et. al., *Ophthalmol.*, 93, 1055 (1986); K. J. Tarbert, *Ophthalmol.*, 102, 1065 (1995); F. E. O'Donnell, Jr., US Pat 5345948 (1994)). External massage of the nasolacrimal duct has also been shown to increase tear transit times through the nasolacrimal duct (J. A. Foster, et. al., *Ophthalm. Plas. Reconstr. Surg.*, 12, 32 (1996)).

Thus, as a result of the ineffectiveness and inconvenience of current therapies, medical researchers have sought to develop alternatives for the treatment of dry eye disorders and nasolacrimal duct disorders. It has been shown that uridine 5'-triphosphate (UTP) and adenine 5'-triphosphate (ATP) are potent agonists of P2Y<sub>2</sub> purinergic receptors found on the surface of human airway epithelium. Activation of these P2Y<sub>2</sub> purinergic receptors induces chloride and water secretion, helping hydrate the airway surface secretions. Use of UTP and ATP for the purpose of treating pulmonary disorders characterized by the retention of lung mucus secretions is described in U.S. Pat. No. 5,292,498. Because of the demonstrated ability of UTP to increase hydration of airway epithelial secretions, applicants were motivated to investigate whether UTP and other P2Y<sub>2</sub> and P2Y<sub>4</sub> purinergic receptor agonists could also stimulate hydration of ocular epithelia. It had previously been shown that P2 type purinergic receptors in rat and mouse lacrimal acinar cells responded to extracellular ATP by increasing intracellular calcium (I.

Sasaki, et al., *Febs Lett.* 264, 130-34 (1990); idem, *J. Physiol.* 447, 103-18 (1992); P. Vincent, *J. Physiol.* 449, 313-31 (1992); J. Gromada, et al., *Eur J. Physiol.* 429, 578 (1995); V. Lee, et al. *Inv. Ophthalm. Vis. Sci.* 38(4)(1997) abstract). Applicant has discovered that tear secretion can be stimulated from lacrimal accessory tissues via P2Y<sub>2</sub> and/or P2Y<sub>4</sub> purinergic receptor-mediated mechanisms similar to those which hydrate airway epithelia. Applicant has also discovered that stimulators of mucociliary clearance when applied topically to the eye or injected into the nasolacrimal drainage system increases the flow of tears through the nasolacrimal duct and hence relieves the symptoms associated with nasolacrimal duct obstruction. UTP and other purinergic receptor agonists, administered topically or systemically, provide a novel method of treating dry eye disorders and nasolacrimal duct obstruction.

### SUMMARY OF THE INVENTION

A method of stimulating tear secretion in a subject in need of such treatment is disclosed. The method of the present invention may be used to increase tear production for any reason, including, but not limited to, treatment of dry eye disease. Dry eye disease is defined to include: keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury, infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin), pharmacologic side effects, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders, and comatose patients rendered unable to blink. The present invention may also be useful as a wash or irrigation solution in conscious individuals, during surgery or to maintain comatose patients or those who cannot blink due to neuromuscular blockade, muscle or nerve damage, or loss of the eyelids. The compound uridine triphosphate (UTP) was found to be a potent agonist of P2Y<sub>2</sub> and P2Y<sub>4</sub> purinergic receptors in lacrimal tissue preparations. Furthermore, an *in vivo* example in accordance with the invention is conducted on an animal (rabbit) model of dry eye disease.

A method of enhancing drainage of the lacrimal system in a subject in need of such treatment is also disclosed. The method of this aspect of the invention may be used to enhance clearance of the nasolacrimal duct for any reason, including, but not limited to, treatment of nasolacrimal duct obstruction. Nasolacrimal duct obstruction is defined to include both primary and secondary acquired nasolacrimal duct obstruction and pediatric nasolacrimal duct obstruction. The present invention may also be useful as a nasolacrimal wash or irrigation solution in conscious individuals or during nasolacrimal duct surgery or intubation. The compounds disclosed herein may also be used in conjunction with mucolytic agents, such as DNase, acetylcysteine and bromhexine.

The method of the present invention comprises topically administering a liquid or gel suspension of P2Y<sub>2</sub> and/or P2Y<sub>4</sub> purinergic receptor agonists selected from



the group consisting of uridine triphosphate [UTP] and its analogs, P<sup>1</sup>P<sup>4</sup>--di(uridine-5')  
tetraphosphate [U<sub>2</sub>P<sub>4</sub>] and its analogs, cytidine 5'-triphosphate [CTP] and its analogs, and  
adenosine 5'-triphosphate [ATP], with the particles of UTP, U<sub>2</sub>P<sub>4</sub>, CTP or ATP  
administered in an amount effective to stimulate tear secretion or enhance clearance of  
5 nasolacrimal ducts.

A second aspect of the present invention is the use of a compound of  
formula I-IV for the manufacture of a medicament for carrying out a therapeutic method  
of treatment as given above.

A third aspect of the present invention is a pharmaceutical composition  
10 comprising a compound of Formula I, II, III or IV, in a pharmaceutical carrier in an  
amount effective to stimulate tear production or to enhance clearance of nasolacrimal  
ducts in a subject in need of such treatment.

### DETAILED DESCRIPTION OF THE INVENTION

The method of the present invention may be used to increase tear production for any reason, including, but not limited to, treatment of dry eye disease. Dry eye disease is defined to include: keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury, infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin), pharmacologic side effects, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders, and comatose patients rendered unable to blink. The present invention may also be useful as a wash or irrigation solution in conscious individuals, during surgery or to maintain comatose patients or those who cannot blink due to muscle or nerve damage, neuromuscular blockade or loss of the eyelids.

A method of enhancing drainage of the lacrimal system in a subject in need of such treatment is also disclosed. The method of this aspect of the invention may be used to enhance clearance of the nasolacrimal duct for any reason, including, but not limited to, treatment of nasolacrimal duct obstruction. Nasolacrimal duct obstruction is defined to include both primary and secondary acquired nasolacrimal duct obstruction and pediatric nasolacrimal duct obstruction. The present invention may also be useful as a nasolacrimal wash or irrigation solution in conscious individuals or during nasolacrimal duct surgery or intubation. The compounds disclosed herein may also be used in conjunction with mucolytic agents, such as DNase, acetylcysteine and bromhexine.

Applicant has discovered that uridine 5'-triphosphate (UTP) is a potent agonist for purinergic receptors found in lacrimal gland and conjunctival preparations. The method of the present invention is an improvement upon the current most commonly used treatment of dry eye disease--artificial tears (i.e., saline solution) because UTP stimulates a patient's own tear production and secretion, which maintain natural protective and lubricant characteristics. Furthermore, the method of the present invention may be

useful even where lacrimal glands are dysfunctional or absent. In addition, the method of the present invention may be useful in enhancing clearance of obstructed nasolacrimal ducts.

The present invention is concerned primarily with the treatment of human subjects, but may also be employed for the treatment of other mammalian subjects, such as dogs and cats, for veterinary purposes.

The term "uridine triphosphate," as used herein, includes the pharmaceutically acceptable salts thereof, such as (but not limited to) an alkali metal salt such as sodium or potassium; an alkaline earth metal salt such as magnesium or calcium; or an ammonium or tetraalkyl ammonium salt, i.e.,  $NX_4^+$  (wherein X is  $C_{1-4}$  alkyl). Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.

The method of the present invention comprises topically administering a liquid or gel suspension of  $P2Y_2$  and/or  $P2Y_4$  purinergic receptor agonists selected from the group consisting of general Formula I, i.e., uridine triphosphate [UTP] and its analogs, general Formula II, i.e.,  $P^1P^4$ --di(uridine-5') tetraphosphate [ $U_2P_4$ ] and its analogs, general Formula III, i.e., cytidine 5'-triphosphate [CTP] and its analogs, and general Formula IV, i.e., adenosine 5'-triphosphate [ATP] and its analogs, with the particles of Formula I, II, III or IV administered in an amount effective to stimulate tear secretion or to enhance clearance of nasolacrimal duct obstruction.

Previously described dinucleotides are listed in Table I, along with their corresponding literature references.

TABLE I

## DINUCLEOTIDES IN THE LITERATURE

(numbers in parentheses correspond to references that follow)

5

Np,N	Np,N'	Np,N	Np,N'	Np,N	Np,N'
Ap <sub>2</sub> A (4,1)	Ap <sub>2</sub> NAD (6)	Up <sub>3</sub> U (1)	Ap <sub>3</sub> T (20)	Up <sub>4</sub> U (2,3)	Ap <sub>4</sub> U (3)
Gp <sub>2</sub> G (5,1)	Ap <sub>2</sub> TAD (6)	Ap <sub>3</sub> A(1,4,29)	m <sup>7</sup> Gp <sub>3</sub> G (5)	Ap <sub>4</sub> A(1,4,29)	Ap <sub>4</sub> C (3)
m <sup>7</sup> Gp <sub>2</sub> m <sup>7</sup> G(5)	Ap <sub>2</sub> C-NAD(6)	Xp <sub>3</sub> X (1)	m <sup>2,2,7</sup> Gp <sub>3</sub> G(5)	Cp <sub>4</sub> C (3)	Ap <sub>4</sub> G (3)
	Ap <sub>2</sub> C-PAD(6)	m <sup>7</sup> Gp <sub>3</sub> m <sup>7</sup> G(5)	m <sup>2,7</sup> Gp <sub>3</sub> G(5)	Gp <sub>4</sub> G (1,5)	Gp <sub>4</sub> U (3)
	Ap <sub>2</sub> BAD (6)	Gp <sub>3</sub> G (1)		Xp <sub>4</sub> X (1)	Gp <sub>4</sub> C (3)
	m <sup>7</sup> Gp <sub>2</sub> G (5)			Dp <sub>4</sub> D (15)	Up <sub>4</sub> C (3)
	Up <sub>2</sub> U (43)			eAp <sub>4</sub> eA (7)	Ap <sub>4</sub> T (20)
				m <sup>7</sup> Gp <sub>4</sub> m <sup>7</sup> G(5)	m <sup>7</sup> Gp <sub>4</sub> G (5)
					m <sup>2,7</sup> Gp <sub>4</sub> G (5)
					m <sup>2,2,7</sup> Gp <sub>4</sub> G(5)


AppZppA	DppZppD	ApZppZpA	ApSpZpSpA
Z	Z	Z	Z
CH <sub>2</sub> (8)	CH <sub>2</sub> (15)	CH <sub>2</sub> (8)	CHF (8)
CH <sub>2</sub> CH <sub>2</sub> (8)	CH <sub>2</sub> CH <sub>2</sub> (15)	CH <sub>2</sub> CH <sub>2</sub> (8)	CF <sub>2</sub> (8)
CHF (8)	CHF (15)	CHF (8)	O (8)
CF <sub>2</sub> (8)	CF <sub>2</sub> (15)	CF <sub>2</sub> (8)	
CHCl (8)	CHCl (15)	CHCl (8)	
CCl <sub>2</sub> (8)	CCl <sub>2</sub> (15)	CCl <sub>2</sub> (8)	

10

A = Adenosine

U = Uracine

G = Guanosine

15

T = Thymidine

X = Xanthosine

TAD = Tiazofurin

BAD = Benzamide riboside

D = 2,6-Diaminopurine

eA = Ethenoadenosine

m<sup>7</sup>G = 7-Methylguanosinem<sup>2,7</sup>G = 2,7-Dimethylguanosinem<sup>2,2,7</sup>G = 2,2,7-Trimethylguanosine

NAD = nicotinamide riboside

C-NAD = C-nicotinamide riboside

C-PAD = C-picolinamide riboside

N = Nucleoside

20

(1) M.A.G. Sillero et al., Eur. J. Biochem., 76, 331 (1977)

(2) C.G. Vallejo et al., Biochim. Biophys. Acta, 483, 304 (1976)

(3) H. Coste et al., J. Biol. Chem., 262, 12096 (1987)

25 (4) K.E. Ng et al., Nucleic Acid Res., 15, 3573 (1987)

(5) J. Stepinski et al., Nucleosides &amp; Nucleotides, 14, 717 (1995)

(6) A. Zatorski et al., J. Med. Chem., 39, 2422 (1996)

(7) P. Rotilan et al., FEBS, 280, 371 (1991)


(8) P.C. Zamecnik et al., Proc. Natl. Acad. Sci., 89, 2370 (1992)

- (9) J. Walker et al., *Biochemistry*, 32, 14009 (1993)  
 (10) R.H. Hideman et al., *J. Biol. Chem.*, 266, 6915 (1991)  
 (11) J. Luthje et al., *Eur. J. Biochem.*, 173, 241 (1988)  
 (12) R.H. Silverman et al., *Microbiological Rev.*, 43, 27 (1979)  
 5 (13) C.D. Lobaton et al., *Eur. J. Biochem.*, 50, 495 (1975)  
 (14) G. Lowe et al., *Nucleosides & Nucleotides*, 10, 181 (1991)  
 (15) G.M. Blackburn et al., *Nucleosides & Nucleotides*, 10, 549 (1991)  
 (16) J.C. Baker et al., *Mutation Res.*, 208, 87 (1988)  
 (17) G. Klein et al., *Biochemistry*, 27, 1897 (1988)  
 10 (18) E. Castro et al., *Br. J. Pharmacol.*, 100, 360 (1990)  
 (19) D.R. Elmaleh et al., *Proc. Natl. Acad. Sci.*, 81, 918 (1984)  
 (20) R. Bone et al., *J. Biol. Chem.*, 261, 16410 (1986)  
 (21) Fed. Amer. Soc. Exper. Bio., Abstr. Part I, no. 1878 (1991)  
 (22) M.T. Miras-Portugal et al., *Ann. NY Acad. Sci.*, 603, 523 (1990)  
 15 (23) A. Guranowski et al., *Biochemistry*, 27, 2959 (1988)  
 (24) F. Grummt et al., *Plant Mol. Bio.*, 2, 41 (1983)  
 (25) A.G. McLennan et al., *Nucleic Acid Res.*, 12, 1609 (1984)  
 (26) P. Zamecnik et al., *Analytical Biochem.*, 134, 1 (1983)  
 (27) E. Rapaport et al., *Proc. Natl. Acad. Sci.*, 78, 838 (1981)  
 20 (28) T. Kimura et al., *Biol. Pharm. Bull.*, 18, 1556 (1995)  
 (29) E. Schulze-Lohoff et al., *Hypertension*, 26, 899 (1995)  
 (30) B.K. Kim et al., *Proc. Natl. Acad. Sci.*, 89, 11056 (1992)  
 (31) P.C. Zamecnik et al., *Proc. Natl. Acad. Sci.*, 89, 2370 (1992)  
 (32) H. Morii et al., *Eur. J. Biochem.*, 205, 979 (1992)  
 25 (33) E. Castro et al., *Pflugers Arch.*, 426, 524 (1994)  
 (34) H. Schluter et al., *Nature*, 367, 186 (1994)  
 (35) E. Castro et al., *Br. J. Pharmacol.*, 206, 833 (1992)  
 (36) T. Casillas et al., *Biochemistry*, 32, 14203 (1993)  
 (37) J. Pintor et al., *J. Neurochem.*, 64, 670 (1995)  
 30 (38) E. Castro et al., *J. Biol. Chem.*, 270, 5098 (1995)  
 (39) V.A. Panchenko et al., *Neuroscience*, 70, 353 (1996)  
 (40) E. Castro et al., *Br. J. Pharmacol.*, 100, 360 (1990)  
 (41) J. Pintor et al., *Gen. Pharmac.*, 26, 229 (1995)  
 (42) J. Pintor et al., *Br. J. Pharmacol.*, 115, 895 (1995)  
 35 (43) A. Kanavarioti et al., *Tett. Lett.*, 32, 6065 (1991)

### Active Compounds of the Invention

UTP and its analogs are depicted in general Formula I:

#### Formula I



wherein:

- 5  $X_1$ ,  $X_2$  and  $X_3$  are each independently either  $O^-$  or  $S^-$ . Preferably,  $X_2$  and  $X_3$  are  $O^-$ .


$R_1$  is O, imido, methylene or dihalomethylene (e.g., dichloromethylene or difluoromethylene). Preferably,  $R_1$  is oxygen or imido.

- 10  $R_2$  is H or Br. Preferably,  $R_2$  is H. Particularly preferred compounds of Formula I are uridine 5'-triphosphate (UTP) and uridine 5'-O-(3-thiotriphosphate) (UTP $\gamma$ S).

A dinucleotide is depicted by the general Formula II:

Formula II

15



20

wherein:

X is oxygen, imido, methylene or difluoromethylene;

$n = 0$  or  $1$ ;

$m = 0$  or  $1$ ;

25


$n + m = 0, 1$  or  $2$ ; and

B and B' are each independently a purine residue or a pyrimidine residue linked through the 9- or 1-position, respectively. In the instance where B and B' are uracil, attached at the N-1 position to the ribosyl moiety, then the total of  $m + n$  may equal 3 or 4 when X is oxygen. The ribosyl moieties are in the D-configuration, as shown, but may be  
30 L-, or D- and L-. The D-configuration is preferred.

B and B' are each independently a purine residue, as in Formula IIa, or a pyrimidine residue, as in Formula IIb, linked through the 9- or 1-position, respectively.

In the instance where B and B' are uracil, attached at the N-1 position to the ribosyl moiety, then the total of  $m + n$  may equal 3 or 4 when X is oxygen. The ribosyl moieties are in the D-configuration, as shown, but may be L-, or D- and L-. The D-configuration is preferred.


Formula IIa



The substituted derivatives of adenine include adenine 1-oxide; 1,N6-(4- or 5-substituted etheno) adenine; 6-substituted adenine; or 8-substituted aminoadenine, where R' of the 6- or 8-HNR' groups are chosen from among: arylalkyl ( $C_{1-6}$ ) groups with the aryl moiety optionally functionalized as described below; alkyl; and alkyl groups with functional groups therein, such as: ([6-aminohexyl]carbamoylmethyl)-, and  $\omega$ -acylated-amino(hydroxy, thiol and carboxy) derivatives where the acyl group is chosen from among, but not limited to, acetyl, trifluoroacetyl, benzoyl, substituted-benzoyl, etc., or the carboxylic moiety is present as its ester or amide derivative, for example, the ethyl or methyl ester or its methyl, ethyl or benzamido derivative. The  $\omega$ -amino(hydroxy, thiol) moiety may be alkylated with a  $C_{1-4}$  alkyl group.

Likewise, B or B', or both may be a pyrimidine with the general formula of Figure IIb, linked through the 1-position:

Figure IIb



wherein:

- $R_4$  is hydroxy, mercapto, amino, cyano, aralkoxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylamino and dialkylamino, the alkyl groups optionally linked to form a heterocycle;
- $R_5$  is hydrogen, acyl,  $C_{1-6}$  alkyl, aroyl,  $C_{1-5}$  alkanoyl, benzoyl, or sulphonate;
- $R_6$  is hydroxy, amino, mercapto, alkoxy, aralkoxy,  $C_{1-6}$ -alkylthio,  $C_{1-5}$  disubstituted amino, triazolyl, alkylamino or dialkylamino, where the alkyl groups are optionally linked to form a heterocycle or linked to  $N^3$  to form an optionally substituted ring;
- $R_7$  is hydrogen, hydroxy, cyano, nitro, alkenyl with the alkenyl moiety optionally linked through oxygen to form a ring optionally substituted on the carbon adjacent to the oxygen with alkyl or aryl groups, substituted alkynyl, halogen, alkyl, substituted alkyl, perhalomethyl (e.g.,  $CF_3$ ),  $C_{2-6}$  alkyl,  $C_{2-3}$  alkenyl, or substituted ethenyl (e.g., allylamino, bromvinyl and ethyl propenoate, or propenoic acid),  $C_{2-3}$  alkynyl or substituted alkynyl; or together  $R_6 - R_7$  may form a 5 or 6-membered saturated or unsaturated ring bonded through N or O at  $R_6$ , such a ring may contain substituents that themselves contain functionalities; provided that when  $R_8$  is amino or substituted amino,
- $R_7$  is hydrogen; and

$R_8$  is hydrogen, alkoxy, arylalkoxy, alkylthio, arylalkylthio, carboxamidomethyl, carboxymethyl, methoxy, methylthio, phenoxy or phenylthio.

- In the general structure of Figure IIb above, the dotted lines in the 2- to 6-positions are intended to indicate the presence of single or double bonds in these positions; the relative positions of the double or single bonds being determined by whether the  $R_4$ ,  $R_6$  and  $R_7$  substituents are capable of keto-enol tautomerism.


In the general structures of Figure IIa and IIb above, the acyl groups advantageously comprise alkanoyl or aroyl groups. The alkyl groups advantageously contain 1 to 8 carbon atoms, particularly 1 to 4 carbon atoms optionally substituted by



one or more appropriate substituents, as described below. The aryl groups including the aryl moieties of such groups as aryloxy are preferably phenyl groups optionally substituted by one or more appropriate substituents, as described below. The above mentioned alkenyl and alkynyl groups advantageously contain 2 to 8 carbon atoms, particularly 2 to 6 carbon atoms, e.g., ethenyl or ethynyl, optionally substituted by one or more appropriate substituents as described below. Appropriate substituents on the above-mentioned alkyl, alkenyl, alkynyl, and aryl groups are advantageously selected from halogen, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl, C<sub>7-12</sub> arylalkoxy, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic, amino and substituted amino wherein the amino is singly or doubly substituted by a C<sub>1-4</sub> alkyl, and when doubly substituted, the alkyl groups optionally being linked to form a heterocycle.

ATP and its analogs are depicted by general Formula III:

Formula III



wherein:

R<sub>1</sub>, X<sub>1</sub>, X<sub>2</sub> and X<sub>3</sub> are defined as in Formula I.


R<sub>3</sub> and R<sub>4</sub> are H while R<sub>2</sub> is nothing and there is a double bond between N-1 and C-6 (adenine), or

R<sub>3</sub> and R<sub>4</sub> are H while R<sub>2</sub> is O and there is a double bond between N-1 and C-6 (adenine 1-oxide), or

R<sub>3</sub>, R<sub>4</sub> and R<sub>2</sub> taken together are -CH=CH-, forming a ring from N-6 to N-1 with a double bond between N-6 and C-6 (1,N6-ethenoadenine).

CTP and its analogs are depicted by general Formula IV:

Formula IV



wherein:

$R_1$ ,  $X_1$ ,  $X_2$  and  $X_3$  are defined as in Formula I.

$R_5$  and  $R_6$  are H while  $R_7$  is nothing and there is a double bond between N-3 and C-4 (cytosine), or

$R_5$ ,  $R_6$  and  $R_7$  taken together are  $-\text{CH}=\text{CH}-$ , forming a ring from N-3 to N-4 with a double bond between N-4 and C-4 (3, $N^4$ -ethenocytosine) optionally substituted at the 4- or 5-position of the etheno ring.

For simplicity, Formulae I, II, III and IV herein illustrate the active compounds in the naturally occurring D-configuration, but the present invention also encompasses compounds in the L-configuration, and mixtures of compounds in the D- and L-configurations, unless otherwise specified. The naturally occurring D-configuration is preferred.

The active compounds of the invention may also be present in the form of their pharmaceutically acceptable salts, such as, but not limited to, an alkali metal salt such as sodium or potassium; an alkaline earth metal salt such as manganese, magnesium or calcium; or an ammonium or tetraalkyl ammonium salt, i.e.,  $\text{NX}_4^+$  (wherein X is  $\text{C}_{1-4}$ ). Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.

### Methods of Administration

The active compounds disclosed herein may be administered to the eyes of a patient by any suitable means, but are preferably administered by administering a liquid or gel suspension of the active compound in the form of drops, spray or gel.

- 5 Alternatively, the active compounds may be applied to the eye via liposomes. Further, the active compounds may be infused into the tear film via a pump-catheter system. Another embodiment of the present invention involves the active compound contained within a continuous or selective-release device, for example, membranes such as, but not limited to, those employed in the Ocusert™ System (Alza Corp., Palo Alto, CA). As an
- 10 additional embodiment, the active compounds can be contained within, carried by, or attached to contact lenses which are placed on the eye. Another embodiment of the present invention involves the active compound contained within a swab or sponge which can be applied to the ocular surface. Another embodiment of the present invention involves the active compound contained within a liquid spray which can be applied to the
- 15 ocular surface. Another embodiment of the present invention involves an injection of the active compound directly into the lacrimal tissues or onto the eye surface.

- The quantity of the active compound included in the topical solution is an amount sufficient to achieve dissolved concentrations of the active compound on the ocular surface of the subject of from about  $10^{-7}$  to about  $10^{-1}$  Moles/liter, and more
- 20 preferably from about  $10^{-6}$  to about  $10^{-1}$  Moles/liter, in order to stimulate tear secretion or enhance clearance of nasolacrimal ducts.

- Depending upon the solubility of the particular formulation of active compound administered, the daily dose to promote tear secretion or enhance clearance of nasolacrimal duct clearance may be divided among one or several unit dose
- 25 administrations. The total daily dose for UTP (for example) may range from a concentration of 0.25 mg/ml to 50 mg/ml, depending upon the age and condition of the subject. A currently preferred unit dose for UTP is about 1 to 100 milligrams given at a regimen of 2 to 6 administrations per day.

Some compounds of Formula I, III and IV can be made by methods which are well known to those skilled in the art; some are commercially available, for example, from Sigma Chemical Company, PO Box 14508, St. Louis, MO 63178. Compounds of Formula II can be made in accordance with known procedures, or variations thereof  
5 which will be described by: P. Zamecnik, et al., *Proc. Natl. Acad. Sci. USA* 89, 838-42 (1981); and K. Ng and L. E. Orgel, *Nucleic Acids Res.* 15(8), 3572-80 (1977).

The topical solution containing the active compound may also contain a physiologically compatible vehicle, as those skilled in the ophthalmic art can select using conventional criteria. The vehicles may be selected from the known ophthalmic vehicles  
10 which include, but are not limited to, saline solution, water polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, petroleum derivatives such as mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as carboxypolymethylene gel, vegetable fats such as peanut  
15 oil and polysaccharides such as dextrans, and glycosaminoglycans such as sodium hyaluronate and salts such as sodium chloride and potassium chloride.

In addition to the topical method of administration described above, there are various methods of administering the active compounds of the present invention systemically. One such means would involve an aerosol suspension of respirable  
20 particles comprised of the active compound, which the subject inhales. The active compound would be absorbed into the bloodstream via the lungs or contact the lacrimal tissues via nasolacrimal ducts, and subsequently contact the lacrimal glands in a pharmaceutically effective amount. The respirable particles may be liquid or solid, with a particle size sufficiently small to pass through the mouth and larynx upon inhalation; in  
25 general, particles ranging from about 1 to 10 microns, but more preferably 1-5 microns, in size are considered respirable.

Another means of systemically administering the active compounds to the eyes of the subject would involve administering a liquid/liquid suspension in the form of eye drops or eye wash or nasal drops of a liquid formulation, or a nasal spray of respirable

particles which the subject inhales. Liquid pharmaceutical compositions of the active compound for producing a nasal spray or nasal or eye drops may be prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water or sterile saline by techniques known to those skilled in the art.

- 5                   Other means of systemic administration of the active compound would involve oral administration, in which pharmaceutical compositions containing compounds of Formula I, II, III or IV are in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to
- 10 the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for
- 15 the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be
- 20 coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate,
- 25 calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

Additional means of systemic administration of the active compound to the eyes of the subject would involve a suppository form of the active compound, such that a

therapeutically effective amount of the compound reaches the eyes via systemic absorption and circulation.

Further means of systemic administration of the active compound would involve direct intra-operative instillation of a gel, cream, or liquid suspension form of a therapeutically effective amount of the active compound.

Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention, as demonstrated by the following examples. In some cases protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general the need for such protecting groups will be apparent to those skilled in the art of organic synthesis as well as the conditions necessary to attach and remove such groups.

The invention is illustrated further by the following examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in it. *In vivo* examples in accordance with the invention are conducted on rabbits with dry eyes. The dry eye disorder is created by surgically closing the duct that carries fluid from the main lacrimal gland to the tear film and surgically removing the nictitans and harderian glands. It is recognized by those skilled in the art that results of ophthalmologic tests carried out on the aforementioned rabbit model have close correlation with humans afflicted with dry eye disease, and, therefore, the results provide an accurate prediction of therapeutic efficacy in humans.

#### Example 1

##### **Stimulation of Mucin Release in Rat Conjunctival Preparations**

Male, Sprague-Dawley rats at 12 weeks of age (Charles River Laboratories, Wilmington, MA) are sacrificed by intraperitoneal injection of sodium pentobarbital (1300 mg/kg) and a 20 $\mu$ L drop of 1% lidocaine diluted with tear buffer (106.5 mM NaCl, 26.1 mM NaHCO<sub>3</sub>, 18.7 mM KCl, 1.0 mM MgCl<sub>2</sub>, 0.5 mM NaH<sub>2</sub>PO<sub>4</sub>, 1.1 mM CaCl<sub>2</sub>, and 10 mM HEPES pH 7.45) is placed on the ocular surface for 10 min. The inferior conjunctiva extending from lid to cornea and medial to lateral canthus is

removed from each eye and placed on filter paper. Each conjunctiva is cut in half longitudinally and the four resulting pieces are incubated in keratinocyte growth medium (Clonetics Corp., San Diego, CA) with or without agonist for 1 hr at 4°C in half strength Karnovsky's solution (2.5% glutaraldehyde and 2% paraformaldehyde in cacodylate buffer, pH 7.4), embedded in methacrylate, and sectioned into 3µm pieces. Six sections from each piece of tissue are stained with Alcian Blue (pH 5) and periodic acid-Schiff's reagent (AB-PAS). The number of mucin-containing goblet cells in each section is counted in masked fashion using light microscopy (standard microscope with a square indexed eye piece reticule) at 160 x magnification. In unstimulated conjunctival tissue culture the goblet cells have defined borders and are intensely stained due to the mucin-containing secretory granules in the apical portion of each goblet cell. Upon stimulation the mucin granules are released into the medium. The number of quiescent mucin-containing goblet cells per unit area (0.16 mm<sup>2</sup>) is counted and averaged. A decrease in the number of mucin-containing goblet cells per unit area indicate an increase in mucin secretion, because the staining is caused by non-secreted cells. Data are expressed as the mean percentage of the value from the control (untreated) tissue. The method of this example is adapted from D. Dartt, et al., *Exp. Eye Res.*, 63, 27 (1996), which is incorporated herein by reference.

### Example 2

#### 20                    **Measurement of Intracellular Calcium**

Rat conjunctival cells grown on vitrogen coated coverslips are loaded with a final concentration of 3 µM Fura-2/AM at 37°C for 30 min. The cells are then washed in NaCl ringer and mounted in a chamber for measurement of fluorescence. To reduce the rate of leakage of Fura-2 from the cell into the extracellular space and avoid time-dependent compartmentalization of the probe, all measurements of [Ca<sup>2+</sup>]<sub>i</sub> are conducted at 25°C. At this temperature, no vesicular bright spots indicative of compartmentalization of the probe are observed.

Measurements of [Ca<sup>2+</sup>]<sub>i</sub> in single rat conjunctival epithelial cells are obtained with a modular microspectrofluorometer (SPEX Industries, Inc., Edison, NJ)

attached to a Zeiss Axiovert IM 35 microscope. The system is equipped with a xenon lamp, beam splitter, two monochromators and a rotating chopper mirror that permit excitation of cell fluorescence at alternating wavelengths of 340 and 380 nm (emission > 450 nm). The fluorescent signal from a single cell is measured with a photometer  
 5 equipped with a pinhole (spot diameter of 3-5  $\mu\text{m}$ ) that exclude signals from adjacent cells.

After agonist is added, the fluorescent signal is quenched by a NaCl ringer solution containing  $1.5 \times 10^{-4}\text{M}$  digitonin and  $10^{-3}\text{M}$   $\text{MnCl}_2$ . The remaining signal at each excitation wavelength, equivalent to the background fluorescence in non-loaded cells, is  
 10 subtracted from data from Fura-2/AM loaded cells before the ratio (340/380 nm) is taken. The 340 nm/380 nm ratio is converted to an actual  $[\text{Ca}^{2+}]_i$  measurement by using the external calibration standards and the formula derived by G. Grynkiewicz, et al. (*J. Biol. Chem.* 260, 3440-3450 (1985)), used with dual wavelength measurements:  $[\text{Ca}^{2+}]_i = K [(R_x - R_0)/(-R_s - R_x)]$ , with  $R_0$  and  $R_s$  representing the ratios at zero  $\text{Ca}^{2+}$  and saturating  
 15  $\text{Ca}^{2+}$ , respectively.  $R_x$  represents the experimental ratio.  $K$  is  $K_d/(F_0/F_s)$ , with  $K_d = 1.57 \times 10^{-7}\text{M}$  at  $25^\circ\text{C}$  as the effective dissociation constant for Fura-2, and  $F_0$  and  $F_s$  represent the fluorescence intensities at 380 nm with zero and saturating  $\text{Ca}^{2+}$ , respectively. The method of this example is adapted from R. Boucher, et al., U.S. Pat. No. 5,292,498, which is incorporated herein by reference.

20

### Example 3

#### **Reversing the Onset of Dry Eye Disease in Rabbit Model for KCS**

Keratoconjunctivitis sicca (KCS) is created in the right eyes of 8 New Zealand white rabbits by surgically closing the lacrimal gland excretory duct, and removing the nictitating membrane, nictitans gland and Harderian gland. All rabbits are  
 25 left untreated for 8 weeks and KCS is confirmed by measuring elevated tear film osmolarity by taking 0.1 - 0.4  $\mu\text{L}$  tear samples as previously described (J. Gilbard, et al., *Ophthalmol.* 96, 677 (1978)). A 3.0 mmol solution of UTP or analog is prepared in a preserved, isotonic buffer solution. Four of the rabbits are treated with 1 drop (10  $\mu\text{L}$ ) UTP or analog solution four times a day, excluding weekends. The remaining 4 untreated



rabbits serve as controls. After treatment began, 0.1 - 0.4  $\mu$ L tear samples are taken from all rabbits for osmolarity measurements on Monday mornings before the first dose. At 20 weeks the animals are sacrificed and goblet cell densities are measured by staining with alcian blue and periodic acid-Schiff's reagent (D. Dartt, et al., *Exp. Eye Res.* 67, 27  
5 (1996)).

The study is designed to demonstrate that UTP and analogs decrease elevated tear film osmolarity and increased conjunctival goblet cell densities, thus reversing the onset of ocular surface disease in a rabbit model for KCS. The method of this example is adapted from J. P. Gilbard, *Arch. Ophthalmol.* 112, 1614 (1994), which is  
10 incorporated herein by reference.

#### Example 4

##### **Acute Ocular Tolerance in Rabbits**

$U_2P_4$  ( $P^i, P^4$ -Di(uridine tetraphosphate), tetrasodium salt) was formulated as an isotonic aqueous solution and topically administered to the eyes of albino rabbits in a  
15 series of experiments to provide a broad indication of the acute ocular safety of  $U_2P_4$ . The experiments were conducted according to GLP guidelines. A modified Draize test was used to determine whether  $U_2P_4$  is acceptable for administration to the eye.

Healthy, male, adult albino New Zealand rabbits (range 2-2.5 kg) were used for these studies. Rabbits were obtained from Elevage Scientifique des Dombes  
20 (Chantillon sur Charlaronne, France). Animals were observed daily for signs of ill health and only healthy animals with no ocular abnormalities were used for experiments. Animals were housed in standard cages in one room under controlled environmental conditions. Animals had free access to food and water throughout the study. The test  
25 article for all studies was daily formulated in water and NaCl to make an isotonic solution.

This experiment was an open trial in which  $U_2P_4$  at a 5.0% concentration was delivered by multiple 50  $\mu$ L instillations (5 times in 20 minutes) into the conjunctival sac of the right eye of three rabbits. Animals were assigned a clinical ocular safety grade for the conjunctiva, cornea and iris according to a modified Draize scale at 0, 1, 2 and 3

hours after the last instillation. The left eye was instilled with physiological saline and served as a control.

The ocular safety results for  $U_2P_4$  at the 5.0% concentration show only one rabbit (both eyes) with slight conjunctival redness (grade 1 on a 0-4 scale of increasing severity). All other grades for conjunctiva, cornea and iris for redness, chemosis and watering were zeros (see Table 2 in appended report). Results for placebo administration were also zeros in all cases.  $U_2P_4$  was thus considered safe for administration to the eye.

#### Example 5


##### **Corneal Anesthesia Effects in Rabbits**

10  $U_2P_4$  ( $P^1, P^4$ -Di(uridine tetraphosphate), tetrasodium salt) was formulated as an isotonic aqueous solution and topically administered to the eyes of albino rabbits to provide a broad indication of the acute ocular safety of  $U_2P_4$ . The experiments were conducted according to GLP guidelines.

Healthy, male, adult albino New Zealand rabbits (range 2-2.5 kg) were  
15 used for these studies. Rabbits were obtained from Elevage Scientifique des Dombes (Chantillon sur Charlaronne, France). Animals were observed daily for signs of ill health and only healthy animals with no ocular abnormalities were used for experiments. Animals were housed in standard cages in one room under controlled environmental conditions. Animals had free access to food and water throughout the study. The test  
20 article for all studies was daily formulated in water and NaCl to make an isotonic solution.

$U_2P_4$  at 5.0% concentration was delivered by multiple 50  $\mu$ L instillations (5 times in 20 minutes) into the conjunctival sac of the right eye of three rabbits and the corneal anesthetic effects evaluated with a Cochet's esthesiometer at 5, 10, 20, 30, 40, 50  
25 and 60 minutes after the last instillation. Corneal anesthesia was evaluated by the number of corneal mechanical stimuli necessary to induce a blinking reflex. The left eye was instilled with physiological saline and served as a control.

The safety of  $U_2P_4$  5.0% solution is demonstrated further, because it showed no corneal anesthetic effects when administered to the right eyes of albino rabbits (see Figure 1).



5 **Figure 1.** The number of mechanical stimuli necessary to induce a blinking reflex is recorded after 5 instillations of 5.0%  $U_2P_4$  is depicted in Figure 1. When compared to saline (left eye),  $U_2P_4$  showed no corneal anesthesia effects.

#### Example 6

10

#### **Tear Secretion in Rabbits**

$U_2P_4$  ( $P^1, P^4$ -Di(uridine tetraphosphate), tetrasodium salt) was formulated as an isotonic aqueous solution and topically administered to the eyes of albino rabbits and tear secretion experiments were conducted as a measure of efficacy in normal rabbits.

15 Healthy, male, adult albino New Zealand rabbits (range 2-2.5 kg) were used for these studies. Rabbits were obtained from Elevage Scientifique des Dombes

(Chantillon sur Charlaronne, France). Animals were observed daily for signs of ill health and only healthy animals with no ocular abnormalities were used for experiments.

Animals were housed in standard cages in one room under controlled environmental conditions. Animals had free access to food and water throughout the study. The test


5 article for all studies was daily formulated in water and NaCl to make an isotonic solution.

$U_2P_4$  at 0.5%, 5.0% and 8.5% concentrations was instilled (50  $\mu$ L) 5 times a day for 14 days into the conjunctival sac of eight rabbits in separate groups. Tear secretion was measured using a Schirmer test strip at 0, 5, 15, 30 and 60 minutes after the

10 first and last instillation of the day on days 1, 7 and 14. The results are compared to separate saline and untreated control groups.

All three concentrations of  $U_2P_4$  increased tear secretion in rabbit eyes over a 60-minute period as compared to saline control (see Figure 2).

15



**Figure 2.** The tear secretion effects for 60 minutes after a single dose of  $U_2P_4$  at three concentrations in rabbit eyes are shown in Figure 2. All three  $U_2P_4$  concentrations increase tear secretion as compared to saline control. The data are shown as the mean of eight animals.

The invention and the manner and process of making and using it are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

**WHAT IS CLAIMED IS:**


1. A sterile preparation adapted for topical administration to the eye comprising:

an effective amount of a compound which activates the purinergic  
 5 receptors in lacrimal tissues, said compound selected from a group consisting of uridine 5'-triphosphate as depicted in Formula I, dinucleotides as depicted in Formulae II, II(a) and II(b) as well as those listed in Table I, adenosine 5'-triphosphate as depicted in Formula III, and cytidine 5'-triphosphate as depicted in Formula IV, as well as their active analogs and derivatives, and their pharmaceutically acceptable salts; and

10 a physiologically compatible vehicle selected from the group consisting of aqueous electrolyte solutions, polyethers, polyvinyls, polymers of acrylic acid, lanolin, and glucosaminoglycans;

whereby said preparation promotes tear secretion from the lacrimal tissues of a subject in need of such treatment:

15

**FORMULA I**

wherein:


$X_1$ ,  $X_2$  and  $X_3$  are each independently either  $O^-$  or  $S^-$ . Preferably,  $X_2$  and  $X_3$  are  $O^-$ .

20  $R_1$  is O, imido, methylene or dihalomethylene (e.g., dichloromethylene or difluoromethylene). Preferably,  $R_1$  is oxygen or imido.

$R_2$  is H or Br. Preferably,  $R_2$  is H. Particularly preferred compounds of Formula I are uridine 5'-triphosphate (UTP) and uridine 5'-O-(3-thiotriphosphate) (UTP $\gamma$ S);

5

FORMULA II



10

wherein:

X is oxygen, imido, methylene or difluoromethylene;

$n = 0$  or  $1$ ;

$m = 0$  or  $1$ ;


15

$n + m = 0, 1$  or  $2$ ; and

B and B' are each independently a purine residue, as in Formula Ia, or a pyrimidine residue, as in Formula Ib, linked through the 9- or 1-position, respectively:

FORMULA II(a)

20




25

wherein:

$R'$  of the 6- or 8-HNR' groups is chosen from the group consisting of arylalkyl ( $C_{1-6}$ ) groups with the aryl moiety optionally functionalized as described below;

alkyl or alkyl groups with functional groups such as ([6-aminohexyl]carbamoylmethyl)-,  $\omega$ -acylated-amino(hydroxy, thiol and carboxy)alkyl( $C_{2-10}$ )- and their  $\omega$ -acylated-amino (hydroxy, thiol and carboxy) derivatives where the acyl group is chosen from the group consisting of acetyl, trifluoroacetyl, benzoyl, substituted-benzoyl or the carboxylic moiety  
 5 is present as its ester or amide derivative;

# FORMULA II(b)



wherein:

R<sub>4</sub> is hydroxy, mercapto, amino, cyano, aralkoxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylamino and dialkylamino, with the alkyl groups optionally linked to form a  
 15 heterocycle;

R<sub>5</sub> is hydrogen, acyl,  $C_{1-6}$  alkyl, aroyl,  $C_{1-5}$  alkanoyl, benzoyl, or sulphamate;

R<sub>6</sub> is hydroxy, mercapto, alkoxy, aralkoxy,  $C_{1-6}$ -alkylthio,  $C_{1-5}$  disubstituted amino, triazolyl, alkylamino or dialkylamino, where the alkyl groups are optionally linked  
 20 to form a heterocycle or linked to N<sup>3</sup> to form an optionally substituted ring;

R<sub>7</sub> is hydrogen, hydroxy, cyano, nitro, alkenyl with the alkenyl moiety optionally linked through oxygen to form a ring optionally substituted on the carbon adjacent to the oxygen with alkyl or aryl groups, substituted alkynyl, halogen, alkyl, substituted alkyl, perhalomethyl (e.g., CF<sub>3</sub>),  $C_{2-6}$  alkyl,  $C_{2-3}$  alkenyl, or substituted ethenyl  
 25 (e.g., allylamino, bromvinyl and ethyl propenoate, or propenoic acid),  $C_{2-3}$  alkynyl or substituted alkynyl; or together R<sub>6</sub> – R<sub>7</sub> may form a 5 or 6-membered saturated or unsaturated ring bonded through N or O at R<sub>6</sub>, such a ring may contain substituents that




themselves contain functionalities; provided that when  $R_8$  is amino or substituted amino,  $R_7$  is hydrogen; and

$R_8$  is hydrogen, alkoxy, arylalkoxy, alkylthio, arylalkylthio, carboxamidomethyl, carboxymethyl, methoxy, methylthio, phenoxy or phenylthio;

5

### FORMULA III



wherein:

$R_1$ ,  $X_1$ ,  $X_2$  and  $X_3$  are defined as in Formula I.

$R_3$  and  $R_4$  are H while  $R_2$  is nothing and there is a double bond between


10 N-1 and C-6 (adenine), or

$R_3$  and  $R_4$  are H while  $R_2$  is O and there is a double bond between N-1 and C-6 (adenine 1-oxide), or

$R_3$ ,  $R_4$  and  $R_2$  taken together are  $-\text{CH}=\text{CH}-$ , forming a ring from N-6 to N-1 with a double bond between N-6 and C-6 (1,N6-ethenoadenine);

15

## FORMULA IV



wherein:

$R_1$ ,  $X_1$ ,  $X_2$  and  $X_3$  are defined as in Formula I.

$R_5$  and  $R_6$  are H while  $R_7$  is nothing and there is a double bond between  
 5 N-3 and C-4 (cytosine), or

$R_5$ ,  $R_6$  and  $R_7$  taken together are  $-\text{CH}=\text{CH}-$ , forming a ring from N-3 to N-4  
 with a double bond between N-4 and C-4 (3, $N^4$ -ethenocytosine) optionally substituted at  
 the 4- or 5-position of the etheno ring.

2. A sterile preparation according to Claim 1, wherein said  
 10 physiologically compatible vehicle is selected from the group consisting of aqueous  
 electrolyte solutions, polyethers, polyvinyls, polymers of acrylic acid, lanolin, and  
 glucosaminoglycans.

3. A sterile preparation according to Claim 1, wherein the acyl groups  
 of Formulae II and III comprise alkyl or aryl groups, the alkyl groups having 1 to 4  
 15 carbon atoms, and the aryl groups including the aryl moieties of such groups as aryloxy  
 are phenyl groups, where the alkyl and aryl groups are substituted with substituents  
 selected from the group consisting of halogen, hydroxy,  $\text{C}_{1-4}$  alkyl,  $\text{C}_{6-12}$  aryl,  $\text{C}_{6-12}$   
 arylalkoxy, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic, amino and  
 substituted amino wherein the amino is singly or doubly substituted by a  $\text{C}_{1-4}$  alkyl, and  
 20 when doubly substituted, the alkyl groups are linked to form a heterocycle.

4. A sterile preparation according to Claim 1, wherein B and B' are uracil attached at the N-1 position to the ribosyl moiety, and wherein the total of m + n may equal 3 or 4 when X is oxygen.
5. A sterile preparation according to Claim 1, wherein the ribosyl  
5 moieties are in the D-configuration.
6. A sterile preparation according to Claim 1, wherein the ribosyl moieties are in the L-configuration.
7. A sterile preparation according to Claim 1, wherein the ribosyl moieties are in the D- and L-configuration.
- 10 8. A sterile preparation according to Claim 1, wherein the dinucleotide is P<sup>1</sup>,P<sup>4</sup>-Di(uridine 5'-P<sup>2</sup>,P<sup>3</sup>-methylenetetraphosphate).
9. A sterile preparation according to Claim 1, wherein the dinucleotide is P<sup>1</sup>,P<sup>4</sup>-Di(uridine 5'-P<sup>2</sup>,P<sup>3</sup>-difluoromethylenetetraphosphate).
- 15 10. A sterile preparation according to Claim 1, wherein the dinucleotide is P<sup>1</sup>,P<sup>4</sup>-Di(uridine 5'-P<sup>2</sup>,P<sup>3</sup>-imidotetraphosphate).
11. A sterile preparation according to Claim 1, wherein the dinucleotide is P<sup>1</sup>,P<sup>4</sup>-Di(4-thiouridine 5'-tetraphosphate).
12. A sterile preparation according to Claim 1, wherein the dinucleotide is P<sup>1</sup>,P<sup>4</sup>-Di(3,N<sup>4</sup>-ethenocytidine 5'-tetraphosphate).
- 20 13. A sterile preparation according to Claim 1, wherein said compound is in the form of particles ranging in size from 1 to 10 microns.
14. A method of stimulating tear secretion from lacrimal tissues comprising the step of administering to the eyes an effective amount of a preparation which includes a compound that activates the purinergic receptors in the lacrimal tissues  
25 of a subject in need of such treatment, said compound selected from a group consisting of uridine 5'-triphosphate, dinucleotides as described by Formulae II, IIa and IIb, cytidine 5'-triphosphate, adenosine 5'-triphosphate and their active analogs and derivatives.

15. A method according to Claim 15, wherein said administration involves topical administration of said compound via a carrier vehicle selected from a group consisting of drops of liquid, liquid wash, gels, ointments, sprays and liposomes.

16. A method according to Claim 16, wherein said topical  
5 administration comprises infusion of said compound to said ocular surface via a device selected from a group consisting of a pump-catheter system, a continuous or selective release device, and a contact lens.

17. A method according to Claim 15, wherein said administration involves systemic administration of said compound by administering a liquid/liquid  
10 suspension of said compound via nose drops or nasal spray or nebulized liquid to oral or nasopharyngeal airways of said subject, such that a therapeutically effective amount of said compound contacts the lacrimal tissues of said subject via systemic absorption and circulation.

18. A method according to claim 18, wherein said systemic  
15 administration of said compound is accomplished by administering an oral form of said compound, such that a therapeutically effective amount of said compound contacts the lacrimal tissues of said subject via systemic absorption and circulation.

19. A method according to claim 18, wherein said systemic administration of said compound is accomplished by administering an injectable form of  
20 said compound, such that a therapeutically effective amount of said compound contacts the lacrimal tissues of said subject via systemic absorption and circulation.

20. A method according to claim 18, wherein said systemic administration of said compound is accomplished by administering a suppository form of said compound, such that a therapeutically effective amount of said compound contacts  
25 the lacrimal tissues of said subject via systemic absorption and circulation.

21. A method according to claim 18, wherein said systemic administration of said compound is accomplished by administering an intra-operative instillation of a gel, cream, powder, foam, crystals, liposomes, spray or liquid suspension

form of said compound, such that a therapeutically effective amount of said compound contacts the lacrimal tissues of said subject via systemic absorption and circulation.

22. A method according to Claim 15, wherein said compound is administered in an amount sufficient to achieve concentrations thereof on the ocular surfaces of said subject of from about  $10^{-7}$  to about  $10^{-1}$  moles/liter.

23. An ophthalmic formulation comprising:  
an effective amount of a compound which activates the purinergic receptors in lacrimal tissues, said compound selected from a group consisting of uridine 5'-triphosphate adenosine 5'-triphosphate, cytidine 5'-triphosphate, dinucleotides as depicted in Formulae I, II and III, their active analogs and derivatives, and their pharmaceutically acceptable salts; and

a physiologically compatible vehicle selected from the group consisting of aqueous electrolyte solutions, polyethers, polyvinyls, polymers of acrylic acid, lanolin, and glucosaminoglycans;  
whereby said formulation promotes nasolacrimal duct drainage.

24. A method according to claim 15, wherein said administration to the eye is carried out in conjunction with surgical procedures comprising probing, silastic intubation or dacryocystorhinostomy.

25. A method according to claim 15, wherein said administration to the eye is carried out in conjunction with mucolytics comprising DNase, acetylcysteine and bromhexine.

26. An ophthalmic formulation comprising:  
an effective amount of a compound which activates the purinergic receptors in lacrimal tissues, said compound selected from a group consisting of uridine 5'-triphosphate adenosine 5'-triphosphate, cytidine 5'-triphosphate, dinucleotides as depicted in Formulae I, II and III, their active analogs and derivatives, and their pharmaceutically acceptable salts; and

a physiologically compatible vehicle selected from the group consisting of aqueous electrolyte solutions, polyethers, polyvinyls, polymers of acrylic acid, lanolin, and glucosaminoglycans;

whereby said formulation provides a treatment for pediatric nasolacrimal duct  
5 obstruction.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/02701

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K9/00

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL no. 75036639, VOVSI, B. M. ET AL. : "Importance of hydrodynamic indices for pathogenic treatment of penetrating wounds of the eye" XP002035486 see abstract ---	1,2, 13-16
X	DE 23 30 902 A (ZANDER, HELMUT) 20 March 1975 see claims 1,2 ---	1,2, 13-16
P,X	WO 97 35591 A (INSPIRE PHARMACEUTICALS) 2 October 1997 see claims 1-23 ---	1-21
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 May 1998

Date of mailing of the international search report

19/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/02701

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 98 03177 A (INSPIRE PHARMACEUTICALS) 29 January 1998 see claims 1-16 ---	1-21
P,X	WO 98 03182 A (INSPIRE PHARMACEUTICALS) 29 January 1998 see claims 1-21 -----	1-21



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/02701

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 2330902 A	20-03-1975	NONE	
WO 9735591 A	02-10-1997	AU 2594897 A	17-10-1997
WO 9803177 A	29-01-1998	NONE	
WO 9803182 A	29-01-1998	NONE	